Clinical features and prognostic factors of intensive and non-intensive 1014 COVID-19 patients: an experience cohort from Alahsa, Saudi Arabia.
Adolescent
Adult
Aged
Aged, 80 and over
Antiviral Agents
/ therapeutic use
COVID-19
/ diagnostic imaging
Child
Child, Preschool
Cohort Studies
Comorbidity
Humans
Infant
Infant, Newborn
Intensive Care Units
Middle Aged
Prognosis
Saudi Arabia
/ epidemiology
Tomography, X-Ray Computed
Treatment Outcome
Young Adult
Admission
COVID-19
Care
Characteristics
Clinical
Critical
ICU
Intensive
Mortality
Outcomes
SARS-CoV-2
Saudi Arabia
Journal
European journal of medical research
ISSN: 2047-783X
Titre abrégé: Eur J Med Res
Pays: England
ID NLM: 9517857
Informations de publication
Date de publication:
24 May 2021
24 May 2021
Historique:
received:
14
02
2021
accepted:
10
05
2021
entrez:
25
5
2021
pubmed:
26
5
2021
medline:
3
6
2021
Statut:
epublish
Résumé
COVID-19 is a worldwide pandemic and has placed significant demand for acute and critical care services on hospitals in many countries. To determine the predictors of severe COVID-19 disease requiring admission to an ICU by comparing patients who were ICU admitted to non-ICU groups. A cohort study was conducted for the laboratory-confirmed COVID-19 patients who were admitted to six Saudi Ministry of Health's hospitals in Alahsa, between March 1, 2020, and July 30, 2020, by reviewing patient's medical records retrospectively. This cohort included 1014 patients with an overall mean age of 47.2 ± 19.3 years and 582 (57%) were males. A total of 205 (20%) of the hospitalized patients were admitted to the ICU. Hypertension, diabetes and obesity were the most common comorbidities in all study patients (27.2, 19.9, and 9%, respectively). The most prevalent symptoms were cough (47.7%), shortness of breath (35.7%) and fever (34.3%). Compared with non-ICU group, ICU patients had older age (p ≤ 0.0005) and comprised a higher proportion of the current smokers and had higher respiratory rates (p ≤ 0.0005), and more percentage of body temperatures in the range of 37.3-38.0 °C (p ≥ 0.0005); and had more comorbidities including diabetes (p ≤ 0.0005), hypertension (p ≥ 0.0005), obesity (p = 0.048), and sickle cell disease (p = 0.039). There were significant differences between the non-ICU and ICU groups for fever, shortness of breath, cough, fatigue, vomiting, dizziness; elevated white blood cells, neutrophils, alanine aminotransferase and alkaline aminotransferase, lactate dehydrogenase, and ferritin, and decreased hemoglobin; and proportion of abnormal bilateral chest CT images (p < 0.05). Significant differences were also found for multiple treatments (p < 0.05). ICU patients group had a much higher mortality rate than those with non-ICU admission (p ≤ 0.0005). Identifying key clinical characteristics of COVID-19 that predict ICU admission and high mortality can be useful for frontline healthcare providers in making the right clinical decision under time-sensitive and resource-constricted environment.
Sections du résumé
BACKGROUND
BACKGROUND
COVID-19 is a worldwide pandemic and has placed significant demand for acute and critical care services on hospitals in many countries.
OBJECTIVES
OBJECTIVE
To determine the predictors of severe COVID-19 disease requiring admission to an ICU by comparing patients who were ICU admitted to non-ICU groups.
METHODS
METHODS
A cohort study was conducted for the laboratory-confirmed COVID-19 patients who were admitted to six Saudi Ministry of Health's hospitals in Alahsa, between March 1, 2020, and July 30, 2020, by reviewing patient's medical records retrospectively.
RESULTS
RESULTS
This cohort included 1014 patients with an overall mean age of 47.2 ± 19.3 years and 582 (57%) were males. A total of 205 (20%) of the hospitalized patients were admitted to the ICU. Hypertension, diabetes and obesity were the most common comorbidities in all study patients (27.2, 19.9, and 9%, respectively). The most prevalent symptoms were cough (47.7%), shortness of breath (35.7%) and fever (34.3%). Compared with non-ICU group, ICU patients had older age (p ≤ 0.0005) and comprised a higher proportion of the current smokers and had higher respiratory rates (p ≤ 0.0005), and more percentage of body temperatures in the range of 37.3-38.0 °C (p ≥ 0.0005); and had more comorbidities including diabetes (p ≤ 0.0005), hypertension (p ≥ 0.0005), obesity (p = 0.048), and sickle cell disease (p = 0.039). There were significant differences between the non-ICU and ICU groups for fever, shortness of breath, cough, fatigue, vomiting, dizziness; elevated white blood cells, neutrophils, alanine aminotransferase and alkaline aminotransferase, lactate dehydrogenase, and ferritin, and decreased hemoglobin; and proportion of abnormal bilateral chest CT images (p < 0.05). Significant differences were also found for multiple treatments (p < 0.05). ICU patients group had a much higher mortality rate than those with non-ICU admission (p ≤ 0.0005).
CONCLUSION
CONCLUSIONS
Identifying key clinical characteristics of COVID-19 that predict ICU admission and high mortality can be useful for frontline healthcare providers in making the right clinical decision under time-sensitive and resource-constricted environment.
Identifiants
pubmed: 34030733
doi: 10.1186/s40001-021-00517-7
pii: 10.1186/s40001-021-00517-7
pmc: PMC8142074
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
47Références
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
BMC Public Health. 2006 Jun 16;6:155
pubmed: 16780576
JAMA. 2020 Sep 8;324(10):998-1000
pubmed: 32789492
Otolaryngol Head Neck Surg. 2020 Jul;163(1):3-11
pubmed: 32369429
Int J Mol Sci. 2020 May 14;21(10):
pubmed: 32423094
Obesity (Silver Spring). 2020 Jul;28(7):1200-1204
pubmed: 32352637
PLoS One. 2021 Mar 16;16(3):e0248009
pubmed: 33724987
JAMA. 2020 Apr 14;323(14):1335
pubmed: 32181795
Br J Haematol. 2020 Jul;190(1):e21-e24
pubmed: 32420608
JACC Case Rep. 2020 Jul 15;2(9):1407-1410
pubmed: 32373791
Lancet. 2020 Oct 24;396(10259):1345-1352
pubmed: 33031764
PLoS One. 2020 Nov 20;15(11):e0242768
pubmed: 33216801
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Emerg Infect Dis. 2020 Aug;26(8):1679-1685
pubmed: 32407284
Transpl Infect Dis. 2020 Oct;22(5):e13407
pubmed: 32654303
Mayo Clin Proc. 2020 Jun;95(6):1124-1126
pubmed: 32451119
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
Lancet Haematol. 2020 Sep;7(9):e632-e634
pubmed: 32563282
J Am Coll Radiol. 2020 Jun;17(6):701-709
pubmed: 32283052
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Head Neck. 2020 Jun;42(6):1252-1258
pubmed: 32342566
J Infect Dis. 2015 Dec 15;212(12):1904-13
pubmed: 26198719
Vaccines (Basel). 2021 Apr 29;9(5):
pubmed: 33946736
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Neurol. 2021 Jan;268(1):240-247
pubmed: 32770412
JAMA. 2020 Apr 28;323(16):1612-1614
pubmed: 32191259
Br J Oral Maxillofac Surg. 2020 Jun;58(5):615-616
pubmed: 32362452
Endocr Pract. 2020 Jun 2;26(6):668-674
pubmed: 32357072
PLoS One. 2020 Jul 30;15(7):e0236618
pubmed: 32730358
Hum Genomics. 2019 Jan 8;13(1):2
pubmed: 30621780
Clin Infect Dis. 2020 Jul 28;71(15):723-731
pubmed: 32227091
Infez Med. 2021 Mar 1;29(1):10-19
pubmed: 33664169
J Neurol. 2021 Mar;268(3):773-784
pubmed: 32761508
J Infect Public Health. 2020 Nov;13(11):1639-1644
pubmed: 33004305
J Clin Med. 2021 Feb 03;10(4):
pubmed: 33546319
Trop Med Infect Dis. 2020 Nov 28;5(4):
pubmed: 33260553
Head Neck. 2020 Jul;42(7):1560-1569
pubmed: 32437022
Emerg Infect Dis. 2020 Oct;26(10):2473-2476
pubmed: 32639228
J Clin Med. 2020 Jun 01;9(6):
pubmed: 32492874
Lancet Diabetes Endocrinol. 2020 Jul;8(7):562-564
pubmed: 32437642
J Infect. 2020 Jul;81(1):147-178
pubmed: 32360498
JAMA. 2020 Apr 21;323(15):1488-1494
pubmed: 32125362
J Infect Public Health. 2020 Jul;13(7):906-913
pubmed: 32546437
Eur Rev Med Pharmacol Sci. 2020 Jul;24(14):7861-7868
pubmed: 32744714
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
JAMA. 2020 Apr 28;323(16):1545-1546
pubmed: 32167538
Eur J Med Res. 2020 Nov 25;25(1):61
pubmed: 33239068
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
J Perinat Med. 2020 Dec 24;49(3):255-261
pubmed: 33554570
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Percept Mot Skills. 2003 Dec;97(3 Pt 1):805-10
pubmed: 14738345
JAMA. 2020 Dec 1;324(21):2149-2150
pubmed: 33175121
PLoS One. 2020 Jul 10;15(7):e0235653
pubmed: 32649661
J Clin Virol. 2020 Jun;127:104354
pubmed: 32305882
AJR Am J Roentgenol. 2020 Jul;215(1):87-93
pubmed: 32174129
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346
pubmed: 32214079
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Front Immunol. 2020 Aug 28;11:2147
pubmed: 32983176
EClinicalMedicine. 2020 Aug;25:100449
pubmed: 32838231
MMWR Morb Mortal Wkly Rep. 2020 Jun 19;69(24):759-765
pubmed: 32555134
Nicotine Tob Res. 2020 Aug 24;22(9):1653-1656
pubmed: 32399563